Long-term idebenone treatment of vascular and degenerative brain disorders of the elderly

Guiseppe Nappi, Giorgio Bono, Paola Merlo, Alessandro Denaro, Roberto Proietti, Nicola Martucci, Mario Fioravanti

Research output: Contribution to journalArticlepeer-review


A multicentre study with an open experimental design was carried out on 118 patients suffering from mild to moderate cognitive decline due to cerebrovascular and degenerative disorders (chronic cerebrovascular disorders, CCVD; multi-infarct dementia, MID; aging brain, AB; dementia of Alzheimer's type, DAT). All patients, after a wash-out period of 3 weeks, were treated with idebenone (45 mg twice daily by oral route) for a period of 6 months. Behavioral and cognitive measures (Sandoz Clinical Assessment of Geriatrics, SCAG; Serial Learning Test) were applied to evaluate the long term therapeutical aspects. The results, analyzed by multivariate analysis of variance and χ2 test, showed a significant improvement of the cognitive profile in all patients, more evident in CCVD and AB groups. No remarkable side-effects were found in all groups of patients, thus confirming good tolerability of idebenone.

Original languageEnglish
Pages (from-to)261-269
Number of pages9
JournalArchives of Gerontology and Geriatrics
Issue number3
Publication statusPublished - 1992


  • Cerebrovascular disorders
  • Cognitive impairment
  • Dementia
  • Idebenone

ASJC Scopus subject areas

  • Ageing
  • Medicine(all)


Dive into the research topics of 'Long-term idebenone treatment of vascular and degenerative brain disorders of the elderly'. Together they form a unique fingerprint.

Cite this